Stoke Therapeutics, Inc. (STOK)
$
33.19
+2.17 (6.54%)
Key metrics
Financial statements
Free cash flow per share
0.7692
Market cap
2 Billion
Price to sales ratio
10.6453
Debt to equity
0
Current ratio
5.2821
Income quality
-6.6219
Average inventory
0
ROE
-0.0205
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing innovative antisense oligonucleotide (ASO) therapies aimed at addressing the root causes of severe genetic diseases in the United States. The company employs its proprietary Targeted Augmentation of Nuclear Gene Output technology to create ASOs that effectively enhance protein expression. Currently, its lead clinical candidate, STK-001, is undergoing a phase I/IIa clinical trial for the treatment of Dravet syndrome, a serious and progressive genetic epilepsy. In addition, STK-002 is in the preclinical stage, targeting autosomal dominant optic atrophy. Stoke Therapeutics has established a license and collaboration agreement with Acadia Pharmaceuticals Inc. to facilitate the discovery, development, and commercialization of novel RNA-based therapies for severe and rare genetic neurodevelopmental disorders affecting the central nervous system. Previously known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016, following its incorporation in 2014. The operating expenses amount to $205,010,000.00 encompassing various operational costs incurred. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations. Moreover, the income before tax ratio is -0.04 which indicates the pre-tax margin. The weighted average number of shares outstanding is 59,219,184.00 highlighting the company's shareholder base. Lastly, the EBITDA ratio is -0.10 showcasing the company's operational efficiency. In the market spectrum, the stock is affordable at $22.90 making it an attractive option for budget-conscious investors. It has a notable average trading volume of 718,472.00 which indicates moderate liquidity for shareholders. With a market capitalization of $1,963,214,687.00 the company is classified as a small-cap player in the stock market. Stoke Therapeutics is a key player in the Biotechnology industry and contributes significantly to the overall market landscape. Additionally, it operates within the Healthcare sector, driving innovation and fostering growth in the biopharmaceutical field.
Is Stoke Therapeutics, Inc. (STOK) a good investment?
Investing in Stoke Therapeutics, Inc. (STOK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Stoke Therapeutics, Inc. (STOK)'s stock forecast?
Analysts predict Stoke Therapeutics, Inc. stock to fluctuate between $5.35 (low) and $40.22 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stoke Therapeutics, Inc.'s market capitalization?
As of 2026-03-19, Stoke Therapeutics, Inc.'s market cap is $1,963,214,687, based on 59,150,789 outstanding shares.
How does Stoke Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Stoke Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Stoke Therapeutics, Inc. (STOK) stock?
To buy Stoke Therapeutics, Inc. (STOK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STOK. Place an order (Market, Limit, etc.).
What is the best time to invest in Stoke Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Stoke Therapeutics, Inc. perform in the last earnings report?
Revenue: $184,420,000 | EPS: -$0.12 | Growth: -92.73%.
Where can I find Stoke Therapeutics, Inc.'s investor relations reports?
Visit https://www.stoketherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stoke Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Stoke Therapeutics, Inc. stock?
All-time high: $40.22 (2026-03-10) | All-time low: $3.35 (2023-10-27).
What are the key trends affecting Stoke Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies.
defenseworld.net
Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,205 shares of the company's stock, valued at approximately $1,062,000. Principal Financial Group Inc. owned approximately
seekingalpha.com
Stoke Therapeutics' TANGO ASO platform can upregulate the functional allele, targeting haploinsufficiency diseases like Dravet and ADOA. This approach gives Zorevunersen disease-modifying features, which I believe will ultimately make it a very competitive asset for Dravet if approved. I believe Zorevunersen is the core value driver. And its Phase 3 EMPEROR plus four-year OLE data suggest durable seizure reductions.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR.
investors.com
Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.
fool.com
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (STOK +12.08%), executed an option exercise and open-market sale of 5,358 common shares for a total consideration of approximately $167,115 on Dec. 4 and Dec. 5, 2025, according to the SEC Form 4 filing.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, November 4, 2025, at 4:30 p.m. E.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA) (n=47). Results were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting and provide important insights into ADOA,.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its Board of Directors has appointed Ian F. Smith as Chief Executive Officer (CEO). Mr. Smith has served as Interim CEO since March 2025 and as a member of Stoke's Board of Directors and advisor to the Company since 2023. He will continue to serve as a Director on the Company's Board.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the following upcoming investor conferences: Cantor Global He.
See all news
